Trials Sponsors Conditions Drugs Pricing

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinomanext-generation sequencingprecision medicine

Outcome Measures

Primary Outcomes (3)

transcriptomic analysis of immune microenvironment
using RNA-seq and multiplex immunofluorescence staining
2 Years
lipotoxic genotyping for SNPs
lipotoxic genotyping for SNPs
2 years
clinical outcomes of MAFLD vs. non-MAFLD.
clinical outcomes of MAFLD vs. non-MAFLD.
2 years

Study Arms (2)

training cohort

Consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-) anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by histology. We will enroll 400 patients who had sufficient tissue for testing in the training cohort.

validation cohort

For the validation cohort, the clinical and pathological information will be obtained retrospectively by TCOG and will take 6 months to identify eligible patients for the 4 sub-groups listed above.

Eligibility Criteria

Age20 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

hepatocellular carcinoma patients

You may qualify if:

Adult female or male patients aged ≥20 years.

Sponsors & Collaborators

National Health Research Institutes, Taiwan
Otherlead
Mackay Memorial Hospital
Othercollaborator
National Cheng-Kung University Hospital

Study Sites (4)

National Cheng-Kung University Hospital

Tainan, Taiwan

National Taiwan University Hospital

Taipei, 100, Taiwan

Mackay Memorial Hospital

Taipei, Taiwan

National Taiwan University Cancer Center

Taipei, Taiwan

Biospecimen

Retention: SAMPLES WITHOUT DNA

next-generation sequencing

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

Tsang-Wu Liu
Taiwan Cooperative Oncology Group, NHRI
STUDY DIRECTOR

Enrollment

579 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

November 1, 2022

First Posted

November 14, 2022

Study Start

August 14, 2025

Actual (reported)

Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Study Arms (2)

training cohort

validation cohort

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (4)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Study Arms (2)

training cohort

validation cohort

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (4)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations